Neuroinflammation and related neuropathologies in APPSL mice: Further value of this in vivo model of Alzheimer's disease

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Löffler, Tina ^a,b   Flunkert, Stefanie ^a   Havas, Daniel ^a   Schweinzer, Cornelia ^a   Uger, Marni ^c   Windisch, Manfred ^a   Steyrer, Ernst ^b   Hutter Paier, Birgit ^a  

^a QPS Austria GmbH   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Amorfix Life Sciences   (Canada)

Author keywords

APPSL; Astrocytosis; A oligomers; A peptides; Correlation analysis; Lipid peroxidation; Microgliosis; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; AMYLOID PRECURSOR PROTEIN; CYTOKINE;

ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN CORTEX; BRAIN TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GLIOSIS; HEMISPHERE; HIPPOCAMPUS; IN VIVO STUDY; LIPID PEROXIDATION; MALE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SPATIAL LEARNING; ANIMAL; COMPLICATION; DISEASE MODEL; ENCEPHALITIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; NEOCORTEX; PATHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALITIS; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; NEOCORTEX; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84900004660     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-84     Document Type: Article

References (62)

1. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991, 12:383-388.
2. Meda L, Cassatella MA, Szendrei GI, Otvos L, Baron P, Villalba M, Ferrari D, Rossi F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995, 374:647-650. 10.1038/374647a0, 7715705.
3. Combs CK, Karlo JC, Kao SC, Landreth GE. beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 2001, 21:1179-1188.
4. Sondag CM, Dhawan G, Combs CK. Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. J Neuroinflammation 2009, 6:1. 10.1186/1742-2094-6-1, 2632990, 19123954.
5. Maezawa I, Zimin PI, Wulff H, Jin LW. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem 2011, 286:3693-3706. 10.1074/jbc.M110.135244, 3030372, 20971854.
6. Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 2008, 28:8354-8360. 10.1523/JNEUROSCI.0616-08.2008, 2597474, 18701698.
7. Liu Z, Condello C, Schain A, Harb R, Grutzendler J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-beta phagocytosis. J Neurosci 2010, 30:17091-17101. 10.1523/JNEUROSCI.4403-10.2010, 3077120, 21159979.
8. White JA, Manelli AM, Holmberg KH, Van Eldik LJ, Ladu MJ. Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis 2005, 18:459-465. 10.1016/j.nbd.2004.12.013, 15755672.
9. Hou L, Liu Y, Wang X, Ma H, He J, Zhang Y, Yu C, Guan W, Ma Y. The effects of amyloid-beta42 oligomer on the proliferation and activation of astrocytes in vitro. In Vitro Cell Dev Biol Anim 2011, 47:573-580. 10.1007/s11626-011-9439-y, 21858610.
10. Pihlaja R, Koistinaho J, Malm T, Sikkila H, Vainio S, Koistinaho M. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease. Glia 2008, 56:154-163. 10.1002/glia.20599, 18004725.
11. Zhao J, O'Connor T, Vassar R. The contribution of activated astrocytes to Abeta production: implications for Alzheimer's disease pathogenesis. J Neuroinflammation 2011, 8:150. 10.1186/1742-2094-8-150, 3216000, 22047170.
12. Mhatre M, Floyd RA, Hensley K. Oxidative stress and neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets. J Alzheimers Dis 2004, 6:147-157.
13. Sochocka M, Koutsouraki ES, Gasiorowski K, Leszek J. Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer's disease: new approach to therapy. CNS Neurol Disord Drug Targets 2013, 12:870-871. 10.2174/18715273113129990072, 23469836.
14. St George-Hyslop PH. Genetic factors in the genesis of Alzheimer's disease. Ann N Y Acad Sci 2000, 924:1-7.
15. Mullan M, Crawford F, Axelman KH. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nat Genet 1992, 1:345-347. 10.1038/ng0892-345, 1302033.
16. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706. 10.1038/349704a0, 1671712.
17. Citron MART, Oltersdorf TILM, Haass C, McConlogue L, Hung Y, Seubert P, Vigo Pelfrey C. Mutation of the ß-amyloid precursor protein in familial Alzheimer's disease increases ß-protein production. Nature 1992, 360:672-674. 10.1038/360672a0, 1465129.
18. Wahlund LO, Basun H, Almkvist O, Julin P, Axelman K, Shigeta M, Jelic V, Nordberg A, Lannfelt L. A follow-up study of the family with the Swedish APP 670/ 671 Alzheimer's disease mutation. Dement Geriatr Cogn Disord 1999, 10:526-533. 10.1159/000017200, 10559570.
19. Sinha S, Lieberburg I. Cellular mechanisms of ß amyloid production and secretion. Proc Natl Acad Sci U S A 1999, 20:11049-11053.
20. Talarico G, Piscopo P, Gasparini M, Salati E, Pignatelli M, Pietracupa S, Malvezzi-Campeggi L, Crestini A, Boschi S, Lenzi GL, Confaloni A, Bruno G. The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease. Dement Geriatr Cogn Disord 2010, 29:484-490. 10.1159/000313541, 20523046.
21. Havas D, Hutter-Paier B, Ubhi K, Rockenstein E, Crailsheim K, Masliah E, Windisch M. A longitudinal study of behavioral deficits in an AbetaPP transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 2011, 25:231-243.
22. Faizi M, Bader PL, Saw N, Nguyen TV, Beraki S, Wyss-Coray T, Longo FM, Shamloo M. Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav 2012, 2:142-154. 10.1002/brb3.41, 3345358, 22574282.
23. Windisch M, Flunkert S, Havas D, Hutter-Paier B. Commentary to the recently published review " Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease" by Li, Evrahimi and Schluesener. Ageing Res Rev 2013, 12(1):116-140. Ageing Res Rev 2013, 12:852-854, 10.1016/j.arr.2012.09.002, 22982398.
24. Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J Neurosci Res 2001, 66:573-582. 10.1002/jnr.1247, 11746377.
25. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577. 10.1001/jama.283.12.1571, 10735393.
26. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999, 46:860-866. 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M, 10589538.
27. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 2003, 100:10417-10422. 10.1073/pnas.1834302100, 193576, 12925731.
28. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985. 10.1038/35050116, 11140686.
29. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002, 5:452-457.
30. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002, 22:6331-6335.
31. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259. 10.1007/BF00308809, 1759558.
32. Terry RD, Masliah E, Salmon DP, Butters N, Deteresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580. 10.1002/ana.410300410, 1789684.
33. Nagy Z, Esiri M, Jobst K, Morris J, King EM, McDonald B, Litchfield S. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 1995, 6:21-31.
34. Dickson D, Crystal H, Bevona C, Honer W, Vincent I, Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995, 16/3:285-304.
35. Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TL, Morris JC. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol 2011, 70:857-861. 10.1002/ana.22608, 3243969, 22162065.
36. Jack CR, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, Pankratz VS, Senjem ML, Gunter JL, Mielke MM, Lowe VJ, Boeve BF, Petersen RC. Brain beta-amyloid load approaches a plateau. Neurology 2013, 80:890-896. 10.1212/WNL.0b013e3182840bbe, 3653215, 23446680.
37. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL., Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013, 12:357-367. 10.1016/S1474-4422(13)70044-9, 23477989, Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group.
38. Burgold S, Bittner T, Dorostkar MM, Kieser D, Fuhrmann M, Mitteregger G, Kretzschmar H, Schmidt B, Herms J. In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks. Acta Neuropathol 2011, 121:327-335. 10.1007/s00401-010-0787-6, 3038220, 21136067.
39. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987, 79:195-200. 10.1016/0304-3940(87)90696-3, 3670729.
40. Carpenter AF, Carpenter PW, Markesbery WR. Morphometric analysis of microglia in Alzheimer's disease. J Neuropathol Exp Neurol 1993, 52:601-608. 10.1097/00005072-199311000-00007, 8229079.
41. Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, Lanzillotta A, Pizzi M, Windisch M. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol 2009, 156:982-993. 10.1111/j.1476-5381.2008.00097.x, 2697723, 19239474.
42. Vijayan VK, Geddes JW, Anderson KJ, Chang-Chui H, Ellis WG, Cotman CW. Astrocyte hypertrophy in the Alzheimer's disease hippocampal formation. Exp Neurol 1991, 112:72-78. 10.1016/0014-4886(91)90115-S, 2013308.
43. Schechter R, Yen SH, Terry RD. Fibrous astrocytes in senile dementia of the Alzheimer type. J Neuropathol Exp Neurol 1981, 40:95-101. 10.1097/00005072-198103000-00002, 7007585.
44. Huttunen HJ, Havas D, Peach C, Barren C, Duller S, Xia W, Frosch MP, Hutter-Paier B, Windisch M, Kovacs DM. The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. J Neuropathol Exp Neurol 2010, 69:777-788. 10.1097/NEN.0b013e3181e77ed9, 2918281, 20613640.
45. Ferretti MT, Bruno MA, Ducatenzeiler A, Klein WL, Cuello AC. Intracellular Abeta-oligomers and early inflammation in a model of Alzheimer's disease. Neurobiol Aging 2012, 33:1329-1342. 10.1016/j.neurobiolaging.2011.01.007, 21414686.
46. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, Van Leuven F. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation 2005, 2:22. 10.1186/1742-2094-2-22, 1274341, 16212664.
47. Abbas N, Bednar I, Mix E, Marie S, Paterson D, Ljungberg A, Morris C, Winblad B, Nordberg A, Zhu J. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J Neuroimmunol 2002, 126:50-57. 10.1016/S0165-5728(02)00050-4, 12020956.
48. Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation 2005, 2:23. 10.1186/1742-2094-2-23, 1276812, 16232318.
49. Sarsoza F, Saing T, Kayed R, Dahlin R, Dick M, Broadwater-Hollifield C, Mobley S, Lott I, Doran E, Gillen D, Anderson-Bergman C, Cribbs DH, Glabe C, Head E. A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol 2009, 118:505-517. 10.1007/s00401-009-0530-3, 2737113, 19360426.
50. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 1989, 24:173-182. 10.1016/0165-5728(89)90115-X, 2808689.
51. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004, 62:925-931. 10.1212/01.WNL.0000115115.98960.37, 15037694.
52. Torres LL, Quaglio NB, de Souza GT, Garcia RT, Dati LM, Moreira WL, Loureiro AP, de Souza-Talarico JN, Smid J, Porto CS, Bottino CM, Nitrini R, Barros SB, Camarini R, Marcourakis T. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2011, 26:59-68.
53. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005, 64:1152-1156. 10.1212/01.WNL.0000156156.13641.BA, 15824339.
54. Arikanoglu A, Akil E, Varol S, Yucel Y, Yuksel H, Cevik MU, Palanci Y, Unan F. Relationship of cognitive performance with prolidase and oxidative stress in Alzheimer disease. Neurol Sci 2013, 34:2117-2121. 10.1007/s10072-013-1346-4, 23479033.
55. Baldeiras I, Santana I, Proenca MT, Garrucho MH, Pascoal R, Rodrigues A, Duro D, Oliveira CR. Oxidative damage and progression to Alzheimer's disease in patients with mild cognitive impairment. J Alzheimers Dis 2010, 21:1165-1177.
56. Puertas MC, Martinez-Martos JM, Cobo MP, Carrera MP, Mayas MD, Ramirez-Exposito MJ. Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia. Exp Gerontol 2012, 47:625-630. 10.1016/j.exger.2012.05.019, 22664577.
57. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001, 60:759-767.
58. Zhang F, Liu J, Shi JS. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol 2010, 636:1-7. 10.1016/j.ejphar.2010.03.043, 20361959.
59. Capiralla H, Vingtdeux V, Zhao H, Sankowski R, Al-Abed Y, Davies P, Marambaud P. Resveratrol mitigates lipopolysaccharide- and Abeta-mediated microglial inflammation by inhibiting the TLR4/NF-kappaB/STAT signaling cascade. J Neurochem 2012, 120:461-472. 10.1111/j.1471-4159.2011.07594.x, 3253186, 22118570.
60. Solberg NO, Chamberlin R, Vigil JR, Deck LM, Heidrich JE, Brown DC, Brady CI, Vander Jagt TA, Garwood M, Bisoffi M, Severns V, Vander Jagt DL, Sillerud LO. Optical and SPION-enhanced MR imaging shows that trans-stilbene inhibitors of NF-kappaB concomitantly lower Alzheimer's disease plaque formation and microglial activation in AbetaPP/PS-1 transgenic mouse brain. J Alzheimers Dis 2014, 40:191-212.
61. Loffler T, Flunkert S, Havas D, Santha M, Hutter-Paier B, Steyrer E, Windisch M. Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice. Neurobiol Aging 2013, 34:2378-2388.
62. Paxinos G, Franklin KBJ. Mouse Brain in Stereotaxic Coordinates - second edition 2001, California, USA: Academic Press Inc.